How to Get Adderall XR in Delaware

Who Can Prescribe Adderall XR in Delaware

Any clinician with an active Delaware medical license and DEA Schedule II registration can write an Adderall XR prescription. That includes physicians (MD/DO), nurse practitioners, and physician assistants.

Delaware grants nurse practitioners full practice authority under Title 24, Chapter 19 of the Delaware Code. This means NPs in Delaware do not need a collaborative agreement with a physician to prescribe Schedule II stimulants, a distinction that separates Delaware from more restrictive states like Georgia or Texas. PAs must maintain a delegation agreement with a supervising physician, and that agreement must explicitly authorize controlled substance prescribing. The supervising physician does not need to be physically present for each encounter, but the agreement must be on file with the Delaware Board of Medical Licensure and Discipline.

A 1999 multisite study (the MTA Cooperative Group trial, N=579) demonstrated that carefully managed medication treatment for ADHD, including mixed amphetamine salts, produced superior symptom reduction compared to behavioral treatment alone over 14 months [1]. This trial shaped prescribing standards still referenced by the American Academy of Pediatrics and the American Psychiatric Association. Delaware prescribers typically follow these same evidence-based protocols when initiating stimulant therapy.

Before writing a prescription, most clinicians in Delaware will require a structured diagnostic evaluation. That usually means a clinical interview using DSM-5 criteria, symptom rating scales (such as the Adult ADHD Self-Report Scale), and a review of childhood history to confirm symptom persistence. Some providers also request collateral information from a family member or partner.

Telehealth Prescribing Rules for Adderall XR in Delaware

Delaware permits telehealth prescribing of Schedule II controlled substances, including Adderall XR, for both new and established patients under state telehealth regulations.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 originally required at least one in-person evaluation before a Schedule II prescription could be issued via telemedicine. During the COVID-19 public health emergency, the DEA issued temporary flexibilities allowing Schedule II telehealth prescribing without a prior in-person visit. As of early 2025, the DEA extended these flexibilities through updated telemedicine rulemaking, and Delaware continues to align with federal policy. Patients should confirm the current federal rule status at the time of their visit.

Delaware-specific telehealth law (Title 24, Section 1769D of the Delaware Code) recognizes audio-video encounters as valid for establishing a prescriber-patient relationship. Audio-only encounters (phone calls) do not meet the standard for initial controlled substance evaluations in most circumstances.

For a telehealth Adderall XR appointment in Delaware, expect the following steps:

1. Complete an intake form with medical history, current medications, and ADHD symptom questionnaires.
2. Attend a synchronous video visit (typically 30 to 60 minutes for an initial evaluation).
3. Provide identification and confirm your Delaware residential address.
4. If diagnosed, receive an electronic prescription sent directly to a Delaware pharmacy.

Electronic prescribing of controlled substances (EPCS) is mandatory in Delaware under Senate Bill 116 (signed 2019). Your prescriber must transmit the Adderall XR prescription electronically to the pharmacy. Paper prescriptions for Schedule II drugs are permitted only under specific exceptions, such as technology failure or veterinary use.

Labs and Medical Screening Before Starting Adderall XR

Most prescribers in Delaware require baseline vital signs and a targeted medical history before initiating stimulant therapy. No single mandatory lab panel exists, but clinical guidelines from the American Academy of Pediatrics recommend cardiovascular screening.

Typical pre-prescribing requirements include:

• Blood pressure and heart rate. Mixed amphetamine salts raise mean systolic blood pressure by approximately 2 to 4 mmHg and heart rate by 3 to 6 bpm according to the FDA-approved labeling for Adderall XR [2]. Patients with uncontrolled hypertension (generally systolic >140 or diastolic >90 mmHg) require blood pressure optimization before starting therapy.
• Cardiac history screen. A personal or family history of sudden cardiac death, structural heart disease, or arrhythmias should be evaluated before prescribing. The AHA/AAP joint statement on cardiac screening prior to stimulant use recommends a focused history rather than routine ECG for low-risk patients [3].
• Thyroid function. Some clinicians check TSH to rule out thyroid disease mimicking ADHD symptoms (restlessness, inattention, fatigue). This is not universally required but is common.
• Hepatic and renal panel. A basic metabolic panel or comprehensive metabolic panel helps identify contraindications, particularly in patients with liver or kidney disease that might alter drug metabolism.
• Urine drug screen. Many Delaware prescribers request a baseline urine drug screen, especially for new patients. This is both a clinical safety measure and a documentation practice for controlled substance monitoring.
• Pregnancy test. For patients of childbearing potential, a pregnancy test is standard. Mixed amphetamine salts carry a Category C designation (now replaced by narrative labeling under the Pregnancy and Lactation Labeling Rule), and animal studies have shown embryotoxic effects at high doses.

Weight should be documented at baseline and monitored at follow-ups. In the MTA study, children treated with stimulant medication showed a mean growth suppression of approximately 1 cm per year and about 2.5 kg less weight gain annually compared to untreated peers over the first 24 months [1]. Adults experience less pronounced effects, but appetite suppression remains the most frequently reported side effect.

Delaware Medicaid and Insurance Coverage for Adderall XR

Delaware Medicaid covers Adderall XR for FDA-approved indications with prior authorization. Expect the PA process to require specific clinical documentation.

The Delaware Division of Medicaid and Medical Assistance (DMMA) uses a preferred drug list (PDL) managed by the state's pharmacy benefits manager. Generic mixed amphetamine salts ER is typically preferred over brand-name Adderall XR. If a prescriber requests brand-name, additional step therapy or clinical justification may be required.

Prior authorization documentation in Delaware generally includes:

• A confirmed DSM-5 diagnosis of ADHD or narcolepsy.
• Documentation that the patient has been evaluated by a qualified clinician (psychiatrist, neurologist, or primary care provider with ADHD training).
• Record of the dose prescribed and clinical rationale for the extended-release formulation.
• For patients under 18, many plans require documentation showing that the prescribing clinician discussed behavioral therapy or parent training as a component of treatment, consistent with AAP clinical practice guidelines updated in 2019 [4].
• For adults, documentation of symptom persistence from childhood (per DSM-5 requirement that several symptoms were present before age 12).

Processing time for PA approval in Delaware Medicaid ranges from 24 to 72 hours for standard requests. Urgent requests (patient without medication and at clinical risk) can be expedited within 24 hours. If denied, the prescriber or patient can file an appeal through the DMMA fair hearing process.

Commercial insurers in Delaware (Highmark, Aetna, Cigna, and others) generally cover generic mixed amphetamine salts ER with standard formulary copays. Brand Adderall XR often falls on a higher tier, with copays ranging from $40 to $75 per month depending on the plan. Manufacturer copay cards can reduce out-of-pocket costs for commercially insured patients, but these cards do not apply to Medicaid, Medicare, or other government-funded plans.

503A Compounding Pharmacies in Delaware

Delaware licenses 503A compounding pharmacies to prepare patient-specific prescriptions, including mixed amphetamine salts, under a valid individual prescription.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act [5]. These pharmacies compound medications based on individual prescriptions from licensed practitioners. They differ from 503B outsourcing facilities, which produce compounded drugs in larger batches without patient-specific prescriptions. In Delaware, both types are regulated, but for Adderall XR alternatives, patients typically work with 503A pharmacies.

Situations where compounding may be relevant include:

• A patient who cannot swallow capsules and needs an oral liquid formulation of mixed amphetamine salts.
• A patient with a documented allergy to a specific inactive ingredient (dye, filler) in commercially available generic or brand products.
• Supply shortages. The FDA has posted multiple shortage notices for mixed amphetamine salts since 2022. During active shortages, 503A compounding pharmacies may prepare mixed amphetamine salts if they can source the active pharmaceutical ingredient from an FDA-registered supplier.

Delaware 503A pharmacies cannot ship compounded controlled substances across state lines without meeting the receiving state's requirements. Within Delaware, a 503A pharmacy can deliver compounded mixed amphetamine salts directly to the patient or have the patient pick up in person. A prescription must specify the exact formulation, dose, and quantity.

Transferring an Adderall XR Prescription to Delaware

Schedule II prescriptions cannot be transferred between pharmacies under federal DEA regulations. This is a hard rule, not a state-level variable. If you are moving to Delaware from another state, you need a new prescription from a Delaware-licensed or federally authorized prescriber.

Here is how to handle the transition practically. Bring your prior medical records, including your most recent evaluation, diagnosis, and prescribing history, to a new Delaware provider. Most clinicians will accept records from an out-of-state prescriber and can issue a new prescription after a brief follow-up evaluation rather than a full diagnostic workup. The American Psychiatric Association practice guidelines support continuity of care when documentation of a prior evaluation is available [6].

If your current prescriber is licensed in both your previous state and Delaware (common with telehealth platforms), they may be able to continue prescribing without interruption, provided they hold an active Delaware medical license and a DEA registration valid in the state.

To avoid gaps in medication, request a 30-day supply from your current prescriber before relocating. Start the process of establishing care with a Delaware provider at least two to three weeks before your current prescription runs out.

Timeline: From First Appointment to Filled Prescription

Most patients in Delaware can go from initial contact to a filled Adderall XR prescription in 7 to 14 days. Some cases move faster. Complex cases take longer.

Typical breakdown:

• Day 1 to 3: Schedule an appointment (telehealth or in-person). Many telehealth platforms offer appointments within 48 hours. In-person psychiatry appointments in Delaware average a 2- to 4-week wait, though primary care providers may have shorter availability.
• Day 3 to 7: Complete the initial evaluation. If diagnosed with ADHD and cleared medically, receive an electronic prescription the same day.
• Day 7 to 10: Pharmacy fills the prescription. Most Delaware retail pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies) carry generic mixed amphetamine salts ER. During supply shortages, filling may require calling multiple pharmacies or using the FDA drug shortage database.
• Day 10 to 14: If prior authorization is required (Medicaid or certain commercial plans), add 1 to 5 business days for PA processing.

The first follow-up visit typically occurs 2 to 4 weeks after starting medication. Delaware prescribers usually prescribe a 30-day supply with no refills for the initial prescription, then reassess before continuing. Once stabilized, some prescribers write 90-day prescriptions (three separate 30-day prescriptions with specified fill dates), which is permitted under DEA regulations for Schedule II substances [7].

Delaware Prescription Monitoring Program

Delaware operates a Prescription Monitoring Program (PMP) through the Office of Controlled Substances. All Schedule II through V prescriptions dispensed in Delaware are reported to the PMP database.

Delaware law requires prescribers to check the PMP before writing a new controlled substance prescription and before each subsequent prescription if more than 90 days have elapsed since the last check. Pharmacists must also query the PMP before dispensing a Schedule II controlled substance.

The PMP is accessible through the Delaware Health Information Network (DHIN) and integrates with most electronic health record systems used in the state. This means your prescriber can check the PMP in real time during your visit without a separate login or workflow interruption.

The PMP exists to reduce diversion and identify patients who may be receiving controlled substances from multiple prescribers simultaneously. It is a standard clinical safety tool. Having a controlled substance history in the PMP is not a barrier to receiving a legitimate prescription. A patient prescribed Adderall XR by one provider with consistent fill patterns will not trigger alerts. Abnormal patterns (overlapping prescriptions from different providers, early fills, escalating quantities) may prompt a prescriber or pharmacist to request additional documentation.

Delaware participates in interstate PMP data sharing through the PMP InterConnect system. If you recently filled a controlled substance in another state, your Delaware prescriber can see that record.